Human T cell responses to Dengue and Zika virus infection compared to Dengue/Zika coinfection

Jessica Badolato-Corrêa, Juan Camilo Sánchez-Arcila, Thiara Manuele Alves de Souza, Luciana Santos Barbosa, Priscila Conrado Guerra Nunes, Monique da Rocha Queiroz Lima, Mariana Gandini, Ana Maria Bispo de Filippis, Rivaldo Venâncio da Cunha, Elzinandes Leal de Azeredo, & Luzia Maria de-Oliveira-Pinto

Abstract

Introduction: Zika virus (ZIKV) and dengue virus (DENV) co-circulated during latest outbreaks in Brazil, hence, it is important to evaluate the host cross-reactive immune responses to these viruses. So far, little is known about human T cell responses to ZIKV and no reports detail adaptive immune responses during DENV/ZIKV coinfection.

Methods: Here, we studied T cells responses in well-characterized groups of DENV, ZIKV, or DENV/ZIKV infected patients and DENV-exposed healthy donors. We evaluated chemokine receptors expression and single/multifunctional frequencies of IFN-γ, TNF, and IL2-producing T cells during these infections. Even without antigenic stimulation, it was possible to detect chemokine receptors and IFN-γ, TNF, and IL2-producing T cells from all individuals by flow cytometry. Additionally, PBMCs' IFN-γ response to DENV NS1 protein and to polyclonal stimuli was evaluated by ELISPOT.

Results: DENV and ZIKV infections and DENV/ZIKV coinfections similarly induced expression of CCR5, CX3CR1, and CXCR3 on CD4 and CD8 T cells. DENV/ZIKV coinfection decreased the ability of CD4+ T cells to produce IFN-γ+, TNF+, TNF+ IFN-γ+, and TNF+ IL2+, compared to DENV and ZIKV infections. A higher magnitude of IFN-γ response to DENV NS1 was found in donors with a history of dengue infection, however, a hyporesponsiveness was found in acute DENV, ZIKV, or DENV/ZIKV infected patients, even previously infected with DENV.

Conclusion: Therefore, we emphasize the potential impact of coinfection on the immune response from human hosts, mainly in areas where DENV and ZIKV cocirculate.

Introduction

Dengue virus (DENV) and Zika virus (ZIKV) belong to Flaviviridae family and both diseases affect significantly human health. These viruses are mainly transmitted by Aedes aegypti or albopictus infected mosquitoes. Other routes of infection, including sexual, maternal, and blood transfusions, have been recently reported for ZIKV [1]. DENV
and ZIKV, like other flaviviruses, are single-stranded, positive-sense RNA viruses with a genome of 10.7 kb and two flanking non-coding regions (5' NCR and 3' NCR). The open reading frame encodes one polyprotein with three structural proteins: capsid, pre-membrane/membrane, and envelope and seven nonstructural proteins: NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5 [2]. Four serotypes of DENV (DENV-1 to -4), antigenically distinct have been described [3]. In ZIKV, two major lineages, African (Nigeria, Senegal, and Uganda strains) and Asian (Malaysia 1966, Yap State 2007, and Cambodia 2010) have been described based on full genome sequences of the ORFs [4]. The four DENV serotypes share approximately 70% amino acid identity with each other, while ZIKV displays an overall 43% homology with DENV (with up to 68% identity for more conserved non-structural proteins) [1].

Dengue incidence has increased 30-fold in the last five decades [5]. Currently, dengue is endemic in 128 countries, most of them developing nations, affecting approximately 3.97 billion people annually [6]. The incidence of dengue increased greatly over the past two decades in Brazil, affecting all regions of the country, except the South [7]. Forty years after its discovery, ZIKV reemerged during a 2007 outbreak on Yap Island in Micronesia, continued in 2013 in French Polynesia [8–10], and in 2014 moved to multiple Pacific islands. At the end of that period, it was introduced to South America [11–15]. In Brazil, the first reports of suspected cases occurred in the Northeast, with a peak during the first quarter of 2015, but it was only confirmed in April 2015. The epidemic continued spreading in May 2016. Since then, autochthonous transmission of ZIKV had been reported in 42 countries and territories in the Region of the Americas [11, 13, 16, 17]. Due to lack of reliable official data, Brazilian Ministry of Health estimated the number of cases based on reports of attack rates from other countries.

Dengue infection may be asymptomatic or cause a febrile illness (dengue fever), accompanied by severe headaches, retro-orbital pain, myalgia, arthralgia, gastro-intestinal complications, liver inflammation, and skin rashes. When fever subsides, patients may develop a more severe life-threatening condition, characterized by an increase in vascular permeability, plasma leakage and hemorrhagic manifestations, leading to hypovolemic shock [18]. Clinical features of ZIKV infection resemble—but are generally milder—those caused by DENV. It could range from asymptomatic infection to a febrile illness characterized by rash, fever, conjunctivitis, arthralgia, and arthritis [10, 14, 19]. Unexpectedly, ZIKV outbreak also had a high attack rate and revealed an association with the appearance of Guillain-Barré syndrome in adults [14, 20] and devastating congenital birth defects, including microcephaly in the developing fetus. It makes of Zika a major emerging public health problem [14, 21, 22].

T cells have an essential role in protection against a variety of infections. Indeed, the development of successful vaccine formulations will require the generation of potent and long-lasting T-cell responses. However, there are still no clearly defined immune correlates of protection for these infections [23]. The role of T cells during dengue infection is still controversial, with studies supporting either an immunoprotective or immunopathological role (reviewed in [24]). Pioneer studies proposed that T cells have a detrimental role during secondary dengue infections in a process termed “original antigenic sin.” Based on this theory, cross-reactive T cells generated during primary infection, which recognize secondary-infected DENV serotype with low affinity, are poorly functional but prone to inducing immunopathology [25]. Thus, cross-reactive memory T cells are present in increased numbers and have a low activation threshold. They may outcompete their naïve subsets that have high affinity for secondary-infected serotype with an overall detrimental outcome for protective immunity [25]. Collectively, studies showed that dengue infection elicits a broad specific T cell response that peaks around day 8–10 from fever onset [24, 26]. Dengue-specific CD8+ T cells are present at higher frequencies compared to their CD4+ counterparts and preferentially target non-structural proteins NS3, NS4b, and NS5, while CD4+ T cells are mainly directed toward the capsid envelope and the secreted protein NS1 [27]. A comparison of amino acid sequences of DENV and ZIKV CD8+ T cell epitopes point out a high sequence homology between the two viruses and suggests that some of these CD8+ epitopes may also exist in ZIKV [24].

Therefore, we evaluated a cohort of well-characterized DENV, ZIKV, or DENV/ZIKV-infected patients and DENV-exposed healthy donors. Molecular and serological methodologies confirmed all infections. Even without specific in vitro antigenic stimulation, DENV, ZIKV, and DENV/ZIKV infections induced expression of CCR5, CX3CR1, and CXC3R3 on CD4+ and CD8+ T cells, indicating an activated status of these cells. However, DENV/ZIKV coinfection decreased the ability of CD4+ T cells to produce IFNγ+, TNF+, TNF+ IFNγ+, and TNF+ IL2+, compared to DENV and ZIKV infections. Finally, a hyporesponsiveness of effector/memory T cells in most of acute patients against DENV NS1 specific antigen might occur due to a clonal exhaustion. We would like to emphasize the potential impact of coinfection on the immune response from a human host.

Materials and Methods

Ethics statement

Human blood samples were obtained after written informed consent from all participants. The study was conducted in accordance to the project approved by the Ethics Committee of Plataforma Brasil, FIOCRUZ (CAAE 13318113 · 7 · 0000 · 5248).
Human blood samples

Blood samples from dengue-exposed individuals were obtained from discarded routine blood donations’ buffy coats at Clementino Fraga Filho University Hospital (Brazil) during 2013. Because these samples were collected anonymously, they were exempt from informed consent. All four healthy adult donors were seronegative for DENV IgM, seropositive for DENV IgG, negative for RT-PCR ZIKV and with no clinical history of infections in the past 3 months, suggesting that donors had experienced at least one DENV infections prior to blood donation. Patients’ blood samples were collected between February and March 2016 in ACD Vacutainer and dry tubes. Physicians at Walfrido Arruda Emergency Care Unit, Coronel Antonino (Mato Grosso do Sul, Brazil) evaluated clinical parameters and classified all infected patients according to WHO, 2009 [18]. All samples were screened for DENV, ZIKV, and CHIKV as a differential diagnosis.

Diagnosis

Serum samples were used for all diagnostic tests described below. For diagnosis of suspect dengue cases, DENV IgM Capture DxSelect™ (Focus Diagnostics, CA, USA) and Platelia™ Dengue NS1 Ag ELISA (BioRad Laboratories, CA, USA) were performed. Molecular detection and serotype typing were performed as previously described [28], by real-time RT-PCR protocol [29] and Simplexa™ Dengue Real Time RT-PCR (Focus Diagnostics, Cypress, CA, USA) according to manufacturer’s protocol. We considered a positive diagnosis for DENV the samples positive for DENV by qRT-PCR or/and Dengue NS1 Ag, as stated above. Dengue patients were considered with primary infection provided being positive for IgM, whether negative for IgG or positive for IgG, provided the rate IgM/IgG was greater than 2.0. Dengue cases considered secondary infection presented IgM/IgG rate less than 2.0 [18]. We considered a positive diagnosis for Zika the samples positive for real-time RT-PCR for ZIKV, as described previously [19]. DENV/ZIKV coinfected patients presented both criteria mentioned above for DENV and Zika positivity. For diagnosis of the suspected chikungunya cases, it was performed anti-CHIKV IgM capture ELISA described by CDC [30] and Brazilian Ministry of Health [31], anti-CHIKV ELISA IgM (Euroimmun, Lubeck, Germany) and molecular RT-PCR protocol for CHIKV as described previously [32]. Patient details are provided in Table 1.

Reagents, proteins, and monoclonal antibodies

A mammalian recombinant DENV Non-Structural-1 (DENV NS1) from all four serotypes was used as stimuli for ELISPOT. This protein was donated by The Native Antigen Company (https://thenativeantigencompany.com/product/dengue-virus-ns1-protein-serotypes-1-4/?doing_wp_cron = 1480736436.0465950965881347656250). Phytohemagglutinin (PHA), phorbol 12-myristate 13-acetate (PMA), ionomycin, Brefeldin A, and Saponin were supplied by Sigma–Aldrich (St. Louis, MO, USA). Detailed information of all mAbs used in this study is listed in Table S1.

PBMC isolation and culture

Briefly, peripheral blood mononuclear cells (PBMCs) and plasma were isolated by Ficoll-Paque™ PLUS density gradient centrifugation (GE Healthcare, Uppsala, Sweden) and frozen in fetal bovine serum (FBS, Gibco, Invitrogen Co, Carlsbad, CA, USA) supplemented with 10% dimethyl sulfoxide (DMSO, Sigma–Aldrich). Cells were thawed on the day of the experiment and were used directly for ex vivo assay as follows.

Extracellular staining

Cells were stained for surface markers (FITC anti-CD3, APC/Cy7 anti-CD4, AmCyan anti-CD8, PE/Cy7 anti-CCR5, Pacific Blue anti-CCR3, Pacific Blue anti-CCR5 and, PerCP anti-CX3CR1, Pacific Blue anti-CXCR5 and, PerCP anti-CXCR3) (Table S1) for 30 min, then washed, fixed with 2% paraformaldehyde, and maintained in PBS. The data were collected using BD™ FACS Aria IIu flow cytometer and analyzed using FlowJo 10 software (Tree Star™).

Intracellular staining (ICS)

For intracellular cytokine staining (ICS), PBMCs (2 × 10^5 cells/well) were incubated without stimuli or with PMA (10 ng/mL)/Ionomycin (1 μg/mL) for 2 h at 37°C. Then, Brefeldin A (10 μg/mL) was added to the cultures and incubated for 4 h. Cells were then washed and stained for extracellular markers for 30 min using BV510 anti-CD3, PECy7 anti-CD4, and PETexasRed anti-CD8. After that, cells were washed and fixed with 2% paraformaldehyde. For ICS, cells were blocked with bovine serum albumin (1% BSA, Sigma–Aldrich), permeabilized with saponin (0.05%) and stained with eFluor® 660 anti-IFNγ, Alexafluor® 700 anti-TNF, and eFluor® 450 anti-IL2 (Table S1). Samples were analyzed on BD™ FACS Aria IIu flow cytometer and analyzed using FlowJo 10 software (Tree Star™).

Ex vivo IFNγ ELISPOT assay

IFNγ enzyme-linked immunosorinent spot (ELISPOT) were performed using DENV-exposed donors’ or acute patients’ thawed PBMCs that were immediately added to ELISPOT plates. Briefly, 96-well plates (Multiscreen HTS; Millipore,
| Patient code | Age (yr) | Gender | Type of infection | Days of disease | Severe DENV (WS/NWS) | qRT-PCR DENV | NS1 | IgM | IgM | qRT-PCR ZIKV | Platelets/mm$^3$ | Leukocytes/mm$^3$ | Lymphocytes/mm$^3$ |
|--------------|----------|--------|-------------------|-----------------|----------------------|--------------|-----|-----|-----|--------------|----------------|----------------|----------------|
| 1            | 39       | Male   | Secondary         | 4               | No (NWS)             | DENV-1 pos    | neg | neg | neg | neg          | 248            | 4400           | 2464            |
| 2            | 47       | Female | Secondary         | 22              | No (WS)              | DENV-1$^d$ neg | pos | neg | neg | neg          | 117            | –              | –              |
| 3            | 69       | Male   | Secondary         | 3               | No (WS)              | DENV-1 pos    | neg | neg | neg | neg          | 98             | 2200           | –              |
| 4            | 27       | Female | Secondary         | 2               | No (NWS)             | DENV-4 neg    | neg | neg | neg | neg          | 209            | 7800           | 1248            |
| 5            | 52       | Female | Primary           | 3               | No (NWS)             | DENV-1 pos    | neg | neg | neg | neg          | 163            | 3400           | 272             |
| 6            | 30       | Female | Secondary         | 6               | No (NWS)             | neg pos       | pos | neg | neg | neg          | 172            | 2700           | 575             |
| Median       | 43       |        |                   | 4               | [3–10]               |               |     |     |     |              | 168            | 3400           | 912             |
| [IQR]        | [29–56]  |        |                   |                 |                      |               |     |     |     |              | [112–219]      | [2450–6100]    |                 |
| 7            | 38       | Female | Secondary         | 5               | neg                  | neg neg       | neg | neg | neg | pos          | 197            | 3900           | 1521            |
| 8            | 28       | Male   | Primary           | 4               | neg                  | neg neg       | neg | neg | neg | pos          | 128            | 3800           | 1330            |
| 9            | 45       | Male   | Secondary         | 3               | neg                  | neg neg       | neg | neg | neg | pos          | 246            | 4000           | 1640            |
| 10           | 60       | Female | Secondary         | 4               | neg                  | neg neg       | neg | neg | neg | pos          | 289            | 6100           | 3416            |
| Median       | 42       |        |                   | 4               | [3–5]                |               |     |     |     |              | 222            | 3950           | 1581            |
| [IQR]        | [31–56]  |        |                   |                 |                      |               |     |     |     |              | [145–278]      | [3825–5575]    | [1378–2972]    |
| 11           | 14       | Male   | Primary           | 2               | No (NWS)             | neg pos       | neg | neg | neg | pos          | 260            | 4600           | 2024            |
| 12           | 46       | Male   | Secondary         | 5               | No (NWS)             | neg pos       | neg | neg | neg | pos          | 151            | 5300           | 2120            |
| 13           | 19       | Female | Secondary         | 8               | No (NWS)             | DENV-1 inconcl | neg | neg | neg | neg          | 296            | 9900           | 2871            |
| 14           | 33       | Female | Secondary         | 8               | No (NWS)             | DENV-1 neg    | neg | neg | neg | neg          | 239            | 6600           | 1848            |
| 15           | 21       | Female | Secondary         | 4               | No (NWS)             | DENV-1 neg    | neg | neg | neg | neg          | 137            | 4700           | 2585            |
| 16           | 48       | Male   | Primary           | 3               | No (NWS)             | DENV-4 pos    | neg | neg | neg | pos          | 147            | 3000           | 870             |
| 17           | 18       | Male   | Secondary         | 2               | No (NWS)             | DENV-1 neg    | pos | neg | neg | pos          | 308            | 6000           | 780             |
| Median       | 21       |        |                   | 4               | [2–8]                |               |     |     |     |              | 239            | 5300           | 2024 [870–2585] |
| [IQR]        | [18–46]  |        |                   |                 |                      |               |     |     |     |              | [147–296]      | [4600–6600]    |                 |

– Data not available.

$^a$Performed by the IgG DENV.

$^b$Days after the initial symptoms.

$^c$WSNWS, dengue fever with warning signs; DENV without warning signs.

$^d$Patient 2 confirmed DENV-1 infection using Simplexa$^\text{TM}$ Dengue Real Time RT-PCR (Focus Diagnostics, Cypress, CA) (CT = 34) even after 22 days of onset of symptoms.
Peripheral venous blood was obtained from 4 DENV-acute patients and 1 late-acute phase disease (with 22 days' illness), 4 ZIKV-acute patients and 7 DENV/ZIKV coinfected acute patients. As shown in Table 1, patient 2 confirmed DENV-1 infection using Simplexa™ Dengue Real Time RT-PCR (Ct, Cycle threshold value = 34.6) even after 22 days of onset of symptoms. All four matched healthy donors were negative for DENV IgM, positive for DENV IgG, and negative for RT-PCR.

ZIKV, so they were referred here as DENV-exposed donors. Thirteen patients (76.5%) had dengue during their lifetime, presumed by the positivity for DENV IgG, in which 5 individuals were from DENV group, 3 from ZIKV, and 5 from DENV/ZIKV coinfection group. Most of DENV- or DENV/ZIKV patients showed a mild clinical form (non-warning signals or NWS) and no fatal cases were observed among the cohort studied. In general, symptoms and signs caused by these viruses were similar among the studied groups, and the patients presented typical symptoms such as fever, rash, arthralgia, myalgia, fatigue, headache, and conjunctival hyperemia. No differences were observed in age, gender distribution or days of disease comparing all groups. Similarly, no differences were seen for platelets, leukocytes, and lymphocytes counts among groups. The serotype DENV-1 was predominant among DENV- or DENV/ZIKV-coinfected patients (80%). Finally, all studied samples were also negative for CHIKV diagnosis. The characteristics of all acute patients are detailed in Table 1.

**DENV, ZIKV, and DENV/ZIKV infection induce an increase of T CD4+ and CD8+ chemokine expression**

Chemokines and their receptors are key drivers of inflammation. Our goal here was to assess the magnitude of T cell activation by ex vivo expression of chemokine receptors, particularly useful for dissecting T-cell subsets with distinct migratory capacity and effector function. As shown in Figure 1, expression of ex vivo chemokine receptors such as CCR5, CX3CR1, and CXCR3 were consistently detected on CD4+ and CD8+ T cells from all acute patients and healthy exposed donors. DENV/ZIKV infected individuals presented higher frequencies of CCR5+ or CX3CR1+ compared to exposed donors. Although not significant ($p = 0.0571$), we observed that DENV or ZIKV infected individuals have a propensity to have high CX3CR1+ frequencies compared to exposed individuals. (Fig. 1b,c). No appreciable differences were detected in CXCR3 expression on CD4+ T cells among all groups (Fig. 1d). Intriguingly, among patients analyzed in DENV group, the lowest values for all chemokine receptors expression on CD4+ T cells were observed for patient 2, in which cells were obtained 22 days post infection, even though viral genome was still detected.

CCR5, CX3CR1, and CXCR3 were detected in higher numbers of circulating CD8+ T cells in all three groups of infected patients in comparison to those exposed donors (Fig. 1f–h). Therefore, regardless of acute viral infection, CD4+ and CD8+ T cells would be readily able to migrate and perform effector function.
Frequency of cytokine-producing T CD4\(^+\) and CD8\(^+\) are differentially regulated in DENV, ZIKV, and DENV/ZIKV infection.

To assess the effector function of T cells by means of cytokine produced, we also evaluated the frequency of cells spontaneously producing TNF, IL2, and IFN\(\gamma\). As shown in Figure 2, even without antigenic in vitro stimulation, we observed low, but detectable, frequencies of IFN\(\gamma\)\(^+\) (0.1–1.6%, minimum to maximum), TNF\(^+\) (0.06–1.3%) and IL2\(^+\) (0.3–1.8%) producing T cells from acute patients and in healthy DENV-exposed donors’ T cells compared between them and with those in exposed healthy controls. The same strategy was used for CD8\(^+\) T cells (f–h). Patient 2 in late acute phase (22 days of illness) was shown as open squares. Statistical significance of differences between groups was determined by using two-tailed Mann–Whitney test, where \(p < 0.05\) were considered significant (‘\(p < 0.05\); **\(p < 0.01\)).

**Figure 1.** Chemokine receptor expression on CD4\(^+\) and CD8\(^+\) T cell populations in acute DENV, ZIKV, and DENV/ZIKV patients. Peripheral blood mononuclear cells (\(2 \times 10^5\)) were stained with mAb against surface markers CD3, CD8, CD4, CCR5, CX3CR1, and CXCR3. The expression of CCR5, CX3CR1, and CXCR3 on CD4\(^+\) (a) and CD8\(^+\) T cells (e) was showed in contour plots from one representative exposed donor, DENV-, ZIKV, and DENV/ZIKV-patients by flow cytometry. Frequency, median, 25th and 75th percentile of CCR5\(^+\) (b), CX3CR1\(^+\) (c), and CXCR3\(^+\) (d) CD4\(^+\) T cells from acute viral patients were compared between them and with those in exposed healthy controls. The same strategy was used for CD8\(^+\) T cells (f–h). Patient 2 in late acute phase (22 days of illness) was show as open squares. Statistical significance of differences between groups was determined by using two-tailed Mann–Whitney test, where \(p < 0.05\) were considered significant (‘\(p < 0.05\); **\(p < 0.01\)).

Frequency of cytokine-producing T CD4\(^+\) and CD8\(^+\) are differentially regulated in DENV, ZIKV, and DENV/ZIKV infection.

To assess the effector function of T cells by means of cytokine produced, we also evaluated the frequency of cells spontaneously producing TNF, IL2, and IFN\(\gamma\).

As shown in Figure 2, even without antigenic in vitro stimulation, we observed low, but detectable, frequencies of IFN\(\gamma\)\(^+\) (0.1–1.6%, minimum to maximum), TNF\(^+\) (0.06–1.3%) and IL2\(^+\) (0.3–1.8%) producing T cells from acute patients and in healthy DENV-exposed donors’ T cells (IFN\(\gamma\), 0.1–0.6%; TNF, 0.1–0.7%; IL2, 0.5–4.9%).

Initially, we evaluated separately the frequency of IFN\(\gamma\), TNF, IL2 producer CD4\(^+\) and CD8\(^+\) T lymphocytes, regardless of their simultaneous production (Fig. 2b–d, g–i). First, we observed a trend toward an increased frequency of total IFN\(\gamma\)\(^+\)CD4\(^+\) T cells in DENV (exception of patient 2, open squares) compared to exposed donors. DENV/ZIKV-patients had similar frequencies of total IFN\(\gamma\)\(^+\)CD4\(^+\) T cells (Fig. 2b). Exposed donors, DENV- and ZIKV-patients had a similar frequency of total TNF\(^+\)CD4\(^+\) T cells, while DENV/ZIKV-patients had significantly decreased frequencies of total TNF\(^+\)CD4\(^+\) T cells compared to exposed donors and DENV-patients (Fig. 2c). A trend toward decreased frequencies of total IL2\(^+\)CD4\(^+\) T cells was seen in all acute patients compared to exposed donors (Fig. 2d).

Then, we evaluated the fractions of each multifunctional cell population expressing all three, any combination of two or single production of cytokines (Fig. 2e and j). Among T CD4\(^+\) lymphocytes, the least prevalent populations with two
functions were IFNγ⁺TNF⁺ and IL2⁺TNF⁺ in DENV/ZIKV-patients compared to exposed donors. Higher frequency of IFNγ⁺TNF⁺ CD4⁺ T cells was observed in DENV⁺ compared to DENV/ZIKV-patients. Finally, we observed increased frequency of single IFNγ⁺CD4⁺ T cell population in ZIKV-patients compared to exposed donors (Fig. 2e).

A similar analysis was applied to CD8⁺ T cells. We detected a significant increase in total IFNγ⁺CD8⁺ T cells frequency in...
Figure 2. Frequency of IFNγ-, TNF-, and IL2-producing CD4⁺ and CD8⁺ T cells in acute DENV, ZIKV, and DENV/ZIKV-patients and exposed donors. Cultures of 2 × 10⁵ PBMCs were stimulated with PMA/Ionomycin or unstimulated (medium) for 6 h in presence of brefeldin in the last 4 h. Then, cells were stained with mAb against surface markers CD3, CD8, CD4, and mAb against intracellular IFNγ, TNF, and IL2. Frequency of IFNγ, TNF, and IL2 on CD4⁺ (a) and CD8⁺ T cells (f) was exhibited in counter plots from one representative exposed donor, DENV-, ZIKV, and DENV/ZIKV-patients by flow cytometry for both conditions. Frequency, median, 25th and 75th percentile of IFNγ⁺ (b), TNF⁺ (c), and IL2⁺ (d) CD4⁺ T cells in unstimulated condition from acute viral patients were compared between them and with those in exposed healthy controls. The same strategy was used (g–i). Patient 2 in late-acute phase (22 days of illness) was show as open squares. Bars represent the median of frequency of CD4⁺ T cells (e) and CD8⁺ T cells (j) expressing each of the seven possible combinations of IFNγ, TNF, and IL2 among the studied groups in unstimulated condition. Statistical significance of differences between groups and comparisons among the multifunctional populations were determined by using two-tailed Mann–Whitney test and represented by lines. Values of p < 0.05 were considered significant (*p < 0.05; **p < 0.01).
DENV/ZIKV-patients compared to exposed healthy donors. A trend toward increased frequency of total IFNγ⁺CD8⁺ T cells was observed in ZIKV and in DENV patients (except for patient 2, open squares) (Fig. 2g). Exposed donors, DENV, ZIKV, and DENV/ZIKV-patients had similar frequency of total TNFα⁺CD8⁺ T cells (Fig. 2h). A decreased frequency trend of total IL2⁺CD8⁺ T cells, similarly to total IL2⁺CD4⁺ T cells, was detected in all acute patients compared to exposed donors (Fig. 2i). Regarding the multifunctional analysis, we only detected a higher frequency of single IFNγ⁺CD8⁺ T cells in DENV- and DENV/ZIKV-patients compared to exposed donors (Fig. 2e). Therefore, we suggest that DENV/ZIKV coinfection may influence differently CD4⁺ and CD8⁺ T cells responses, an effect mainly observed in the frequencies of CD4⁺IFNγ⁺TNFα⁺, CD4⁺TNFα⁺IL2⁺, and CD8⁺ total IFNγ⁺ populations.

DENV-specific response targeting NS1 proteins was rarely detectable in acute patients

We used DENV NS1 protein to evaluate DENV-specific response in acute patients because ZIKV and DENV NS1 share 53–56% of amino acid identity [33]. Moreover, NS1 has gained considerable attention for early dengue diagnostic tests. All healthy donors and 75% of acute patients in our cohort had indications of previous dengue, thus it was expected that they would be great responders of NS1 DENV. Considering this, we assessed DENV-specific T cell response against a pool of NS1 from all four serotypes in PBMCs isolated from acute patients from DENV-exposed donors by IFNγ ELISPOT assay (Fig. 3a).

Our initial objective was to compare NS1 DENV-specific memory response from dengue-exposed donors with dengue-infected individuals. Our data indicate that DENV

![Figure 3](image_url)

**Figure 3.** DENV-specific cells targeting DENV 1–4 NS1 protein in acute DENV, ZIKV, and DENV/ZIKV-patients, and donors experiencing dengue. Peripheral blood mononuclear cells (2 × 10⁶ in 0.1 mL) were incubated with recombinant mammalian (rm) NS1 (0.1 μg/mL) derived from four different DENV serotypes or PHA for 20 h and IFNγ production was measured by ELISPOT assay. (a) Representative IFNγ production from one representative exposed donor, DENV, ZIKV, and DENV/ZIKV-patients are shown against rmNS1. (b) The values obtained of IFNγ production, expressed as spot-forming cells (SFC) relative to 10⁶ PBMC, is shown for the rmNS1 and PHA were compared between them and with those in exposed healthy controls. Graphs show the median, 25th and 75th percentile from acute-patients and DENV-exposed ZIKV naive donors. Statistical significance was determined by using the two-tailed Mann–Whitney test, where p < 0.05 were considered significant (*p < 0.05; **p < 0.01).
NS1 memory response had the highest frequencies and magnitude in healthy dengue-exposed donors compared to those with active DENV infection. Among DENV-infected patients, the 22-days DENV patient 2 showed the best response to NS1, indicating that latter phases of dengue could be a better time point for evaluating specific cell responses through ELISPOT. Our second goal was to determine whether active ZIKV infection could affect the NS1 DENV-specific memory response in two different situations: in DENV-exposed patients or in those who have current ZIKV or DENV/ZIKV infections. Our data showed that DENV NS1 was not able to induce a response in any acute active ZIKV-patients, even the samples being positive for Denga IgG ELISA test. Two out five DENV/ZIKV-patients responded with above 50 IFNγ SFC following DENV NS1 stimulation, while the other three responded with below 20 IFNγ SFC after stimulation (Fig 3b). Finally, the magnitude of IFNγ SFC response was not statistically different among the groups of acute patients. In order to understand the specificity of this response, we intend to evaluate healthy donors exposed to Zika in the future.

Discussion

Although T lymphocytes are not infected by DENV and appear not to be infected by ZIKV [34], the impact of each one and of the DENV/ZIKV coinfection seem to affect their function. To address this investigation, we attempted to analyze some features of CD4+ and CD8+ T cell response in PBMC from patients in a cohort of DENV only, ZIKV only and DENV/ZIKV coinfected patients. Our work began with extensive fieldwork in the Midwest region of Brazil in 2016. There, 134 suspected cases of dengue or Zika with an acute febrile illness were recruited, including those with by at least two of the signs and symptoms (headache, myalgia or arthralgia, rash, pruritus, retro-orbital pain, and prostration). Methods of serology and molecular biology have been designed to diagnose the etiologic agent. Of the suspected cases, 6% of them confirmed ZIKV alone, 50% DENV, 22% were coinfected DENV/ZIKV, the others chikungunya, coinfections or not confirmed cases. At this point we realize that we did not have a larger number of samples with zika alone (Azeredo et al. data in submission). Therefore, we analyzed small numbers of individuals in each studied group to match ZIKV-infected patients’ number, even though aware of the possible impact on dispersion of variables such as age, gender, and others because of a reduced number of donors. Despite that, we could report for the first time some aspects of DENV/ZIKV coinfection and compare then to DENV and ZIKV only infections, as well as healthy donors. Herein, our data reported from 17 well-characterized patients infected by DENV, ZIKV or DENV/ZIKV and 4 healthy donors.

Our research evaluated the expression of chemokine receptors on T cells. Chemokine receptors have been useful for dissecting T-cell subsets with distinct migratory capacity and effector function [35]. We assessed the effector as well as memory T cells by an increased expression of CCR5, CX3CR1, or CXCR3, in contrast to their T naive precursors. CCR5 and CXCR3 are closely linked to Th1 function on activated CD4+, memory/activated CD8+ T cells, and NK cells [36–38]. Our data confirmed an increased expression of CCR5 on T cells from acute dengue patients [39, 40]. CCR5 expression would be promoting an enhanced T cell recruitment into the liver, a hypothesis that was corroborated by a high frequency of CCL5+ cells in hepatic tissue from dengue fatal cases [40]. It is widely accepted that CCR5 is part of host’s immune response in the dengue, its role, mediating the traffic of immune cells from blood to target tissues or acting directly on the antiviral response, is still unknown. A recent study demonstrated CX3CR1-based transcriptome and proteome-profiling defined a core signature of memory CD8+ T cells with cytotoxic effector function [41]. Highly polarized CX3CR1+ cytotoxic CD4+ T cells was specifically expanded in exposed donors and, in particular, in those donors carrying an HLA allele associated with protection from severe dengue [42]. By the fact that an increased frequency of CD4 and CD8 T cells expressing CX3CR1 in patients with DENV and, for the first time, in patients with ZIKV and DENV/ZIKV, our data could indicate a potential cytotoxic capacity of T cells from these in acute patients. The protective role of CXCR3 against DENV infection has been demonstrated in experimental models since CXCR3−/− mice infected by DENV presented a higher mortality rates than the wild-type mice. Moreover, brains of CXCR3−/− mice showed higher viral loads and quantitatively fewer CD8+ T cells than those of wild-type mice [43]. We hypothesize that an increase in the frequency CD4+ and CD8+ T cells expressing chemokine receptors would contribute to regulate virus progression through a precise control of inflammatory cells targeting the affected tissue. Thus, chemokine receptors would play a more immunoprotective role once T cells could exert an antiviral, effector, cytotoxic, and migratory activities.

The frequency of IFNγ-producing T cells has been the most used parameter to assess an effective immune or vaccine-induced response. Similarly to IFNγ, TNF is capable of mediating the killing of a variety of intracellular infectious viruses, bacteria, and parasites [44, 45]. Although IL2 has little direct effector function, it promotes the expansion of CD4+ and CD8+ T cells, amplifying any potential effector T cell responses. Importantly, it has been demonstrated that frequency of cytokine-producing T cells alone is not sufficient to predict protection. To provide prospective evidence of the quality of T cell response, vis-à-vis multifunctional T cells is required [23]. Regarding dengue, compelling evidence of the importance of multifunctional
T-cells to mediate protection was found in Flavivirus-naïve volunteers vaccinated with live, attenuated DENV-1 vaccine, rDEN1A30. The authors observed that multifunctional T cells increased significantly in non-viremic subjects tended to have a higher frequency of multifunctional T cells compared to viremic subjects. Therefore, the presence of multifunctional T cells following rDEN1A30 vaccine safely and effectively prompt immune responses associated with control of infection and protection from re-infection [46].

Finally, we studied the magnitude of IFNγ response to DENV NS1. Gideon's team did not observe differences in IFNγ induction between peptide pools and recombinant proteins in overnight ELISPOT assay using PBMC from the same donors [47]. A higher magnitude of IFNγ response to DENV NS1 was found in experienced dengue donors, but a hyporesponsiveness was found in any acute viruses, even experiencing dengue. In 2001, our group described a reduced frequency of CD4⁺ and CD8⁺ T lymphocytes and a poor ability for T-lymphocyte proliferation in response to mitogens and dengue antigens in acute DENV-infected patients, but re-established in convalescence phase [48]. Another study found that in vitro exposure to DENV-2 of T lymphocytes isolated from healthy donors reduces the lymphoproliferative capacity in response to mitogen, suggesting that DENV-2 can inhibit T cell-mediated immunity, bypassing monocytes and dendritic cells, classical DENV cell targets [49].

Briefly, mono- and coinfections similarly induced expression of CCR5, CX3CR1, and CXCR3 on CD4⁺ and CD8⁺ T cells. This could promote functional and migratory similarities of these cells, regardless of the infecting virus. However, DENV/ZIKV coinfection decreased the ability of CD4⁺ T cells to produce IFNγ⁺, TNF⁺, TNF⁺IFNγ⁺, and TNF⁺IL2⁺, compared to monoinfections. We suppose two antagonistic scenarios: infected people are more immunocompromised than those monoinfected, so coinfection would be the worst scenario for those individuals. Another example of potential adverse effects of this immunosuppression is, that a reduced capacity to activate CD4⁺IFNγ⁺TNF⁺ and CD4⁺TNF⁺IL2⁺ T cell populations might interfere with future development of specific or cross-reactive memory lymphocytes, leading to a weak response in a subsequent encounter to other potential arbovirus. In the other scenario, coinfected people have a less inflammatory milieu than monoinfected people. This could mean that a reduced inflammatory condition could avoid harmful effects like cytokine storm. Nevertheless, once the clinical outcome of the patients was similar, it was not possible to associate the symptoms and clinical signs with the immune profile of each group.

Acknowledgments

We would like to thank the Flow Cytometry and cell sorting core RPT08A and ELISPOT Plataforma (PDTIS/FIOCRUZ) for antibody and acquisition support. We gratefully thank the voluntarily participation in this study of healthy individuals at the Clementino Fraga Filho University Hospital (Rio de Janeiro, Brazil) and patients from Walfrido Arruda Emergency Care Unit, Coronel Antonio (Mato Grosso do Sul, Brazil). Also, we thank to Physicians at the Walfrido Arruda Emergency Care Unit, Coronel Antonio evaluated clinical parameters and classified all infected-patients according to WHO and Brazilian Ministry of Health. This work was financially supported by IOC/ FIOCRUZ and FAPERJ. Juan Camilo Sánchez-Arcila is recipient of Post-doctoral fellowship FAPERJ E-26/202.011/2016.

Authors' Contributions

JBCdS, JCSA, ELdA, and LMdOP performed experiments, reviewed data, and planned the experimental strategy. MG collected data using a FACS ARIA BD flow cytometer. ABdP, JBCdS, TMAdSEP, LBdS, PCGN, and MdRQL performed all diagnostic tests. RVdC, JBCdS, TMAdS, LBdS, and ELdA collected samples and provided clinical information. JBCdS, JCSA, and LMdOP conceived and directed the study, and wrote the manuscript. All authors have critically read and edited the manuscript.

Conflicts of Interest

The authors declare no conflicts of interest.

References

1. Lazear, H. M., and M. S. Diamond. 2016. Zika virus: new clinical syndromes and its emergence in the western hemisphere. J. Virol. 90:4864–4875.
2. Kuno, G., and C. G-JJ. 2007. Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika viruses. Arch. Virol. 152:687–696.
3. Guzmán, M. G., and G. Kouri. 2002. Dengue: an update. Lancet Infect. Dis. 2:33–42.
4. Haddow, A. D., A. J. Schuh, C. Y. Yasuda, M. R. Kasper, V. Heang, R. Huy, H. Guzman, R. B. Tesh, and S. C. Weaver. 2012. Genetic characterization of zika virus strains: geographic expansion of the asian lineage. PLoS Negl. Trop. Dis. 6:e1477.
5. WHO. Dengue Fact Sheet. http://www.searo.who.int/vector_borne_tropical_diseases/data/data_factsheet/en/ (2017, accessed 24 February 2017).
6. Bhatt, S., P. W. Gething, O. J. Brady, J. P. Messina, A. W. Farlow, C. L. Moyes, J. M. Drake, J. S. Brownstein, A. G. Hoen, O. Sankoh, et al. 2013. The global distribution and burden of dengue. Nature 496:504–507.
7. Rodrigues, N. C. P., V. T. S. Lino, R. P. Daumas, M. K. de N. Andrade, G. O’Dwyer, D. L. M. Monteiro, A. Gerardi, G. H. B. V. Fernandes, J. A. S. Ramos, C. E. G. Ferreira, et al. Temporal and spatial evolution of dengue incidence in Brazil, 2001–2012. PLoS ONE 11. https://doi.org/10.1371/journal.pone.0165945. [Epub ahead of print].

8. Aubry, M., J. Finke, A. Teissier, C. Roche, J. Broult, S. Paulous, P. Després, V.-M. Cao-Lormeau, and D. Musso. 2015. Seroprevalence of arboviruses among blood donors in French Polynesia, 2011–2013. Int. J. Infect. Dis. IIJD Off. Publ. Int. Soc. Infect. Dis. 41:11–12.

9. Cao-Lormeau, V.-M., and D. Musso. 2014. Emerging arboviruses in the Pacific. Lancet 384:1571–1572.

10. Duffy, M. R., T.-H. Chen, W. T. Hancock, A. M. Powers, J. L. Kool, R. S. Lanciotti, M. Pretrick, M. Marfel, S. Holzbauer, C. Dubray, et al. 2009. Zika virus outbreak on yap island, federated states of Micronesia. N. Engl. J. Med. 360:2536–2543.

11. Campos, G. S., A. C. Bandeira, and S. I. Sardi. 2015. Zika virus outbreak, bahia, Brazil. Emerg. Infect. Dis. 21:1885–1886.

12. Lednicky, J., V. M. Beau De Rochars, M. El Badry, J. Loeb, T. Telisma, S. Chavannes, G. Anilis, E. Cella, M. Ciccozzi, M. Rashid, et al. 2016. Zika virus outbreak in haiti in 2014: molecular and clinical data. PLoS Negl. Trop. Dis. 10: e0004687.

13. Zanluca, C., V. C. A. Melo, A. L. P. Mosimann, G. I. V. D. Santos, C. N. D. D. Santos, and K. Luz. 2015. First report of autochthonous transmission of Zika virus in Brazil. Mem. Inst. Oswaldo Cruz 110:569–572.

14. Pierson, T. C., and B. S. Graham. 2016. Zika virus: immunity and vaccine development. Cell 167:625–631.

15. Metsky, H. C., C. B. Matranga, S. Wohl, S. F. Schaffner, C. A. Freije, S. M. Winnicki, K. West, J. Qu, M. L. Baniecki, A. Gladden-Young, et al. 2017. Zika virus evolution and spread in the Americas. Nature 546:411–415.

16. Azevedo, R. S. S., M. T. Araujo, A. J. Martins Filho, C. S. Oliveira, B. T. D. Nunes, A. C. R. Cruz, A. G. P. A. C. Nascimento, R. C. Medeiros, C. A. M. Caldas, F. C. Araujo, et al. 2016. Zika virus epidemic in Brazil. I. Fatal disease in adults: clinical and laboratorial aspects. J. Clin. Virol. Off. Publ. Pan. Am. Soc. Clin. Virol. 85:56–64.

17. Brito, C. 2015. Zika virus: a new chapter in the history of medicine. Acta Med. Port. 28:679–680.

18. WHO and the Special Programme for Research and Training in Tropical Diseases (TDR). Dengue guidelines for diagnosis, treatment, prevention and control: new edition. http://www.who.int/tdr/publications/guidelines/9789241547871/en/. (2009, accessed 13 February 2017).

19. Lanciotti, R. S., O. L. Kosoy, J. J. Laven, J. O. Velez, A. J. Lambert, A. J. Johnson, S. M. Stanfield, and M. R. Duffy. 2008. Genetic and serologic properties of zika virus associated with an epidemic, yap state, Micronesia, 2007. Emerg. Infect. Dis. 14:1232–1239.

20. Cao-Lormeau, V.-M., A. Blake, S. Mons, S. Lastère, C. Roche, J. Vanhomwegen, T. Dub, L. Baudouin, A. Teissier, P. Larre, et al. 2016. Guillain-Barré Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet Lond. Engl. 387:1531–1539.

21. Johansson, M. A., L. Mierz-Teran-Romero, J. Reehuis, S. M. Gilboa, and S. L. Hills. 2016. Zika and the risk of microcephaly. N. Engl. J. Med. 375:1–4.

22. Kleber de Oliveira, W., J. Cortez-Escalante, W. T. G. H. De Oliveira, G. M. I. do Carmo, C. M. P. Henriques, G. E. Coelho, and G. V. Araújo de França. 2016. Increase in reported prevalence of microcephaly in infants born to women living in areas with confirmed zika virus transmission during the first trimester of Pregnancy—Brazil, 2015. MMWR. Morb. Mortal. Wkly. Rep. 65:242–247.

23. Seder, R. A., P. A. Darrah, and M. Roederer. 2008. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 8:247–258.

24. Rivino, L. 2016. T cell immunity to dengue virus and implications for vaccine design. Expert Rev. Vaccines 15:443–453.

25. Mongkolsapaya, J., W. Dejnirattisai, X. Xu, S. Vasana-watana, N. Tangthawornchaikul, A. Chairunrni, S. Sawasdi-vorn, T. Duangchinda, T. Dong, S. Rowland-Jones, et al. 2003. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9:921–927.

26. Simmons, C. P., T. Dong, N. V. Chau, N. T. P. Dung, T. N. B. Chau, L. T. T. Thao, N. T. Dung, T. T. Hien, S. Rowland-Jones, and J. Farrar. 2005. Early T-cell responses to dengue virus epitopes in Vietnamese adults with secondary dengue virus infections. J. Virol. 79:5665–5675.

27. Rivino, L., A. Tan, A. Chia, E. A. P. Kumaran, G. M. Grottenbreg, P. A. MacAry, and A. Bertoletti. 2013. Defining CD8+ T cell determinants during human viral infection in populations of Asian ethnicity. J. Immunol. Baltim. Md. 190:4010–4019.

28. Lanciotti, R. S., C. H. Calisher, D. J. Gubler, G. J. Chang, and A. V. Vorndam. 1992. Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction. J. Clin. Microbiol. 30:545–551.

29. Johnson, B. W., B. J. Russell, and R. S. Lanciotti. 2005. Serotype-specific detection of dengue viruses in a fourplex real-time reverse transcriptase PCR assay. J. Clin. Microbiol. 43:4977–4983.

30. CDC. Revised diagnostic testing for Zika, chikungunya, and dengue viruses in US Public Health Laboratories.

31. Ministério da Saúde (Brasil). Febre de Chikungunya manejo clinico. http://bvsms.saude.gov.br/bvs/publicacoes/febrecichungunya_manejo_clinico.pdf. (2015).

32. Lanciotti, R. S., O. L. Kosoy, J. J. Laven, A. J. Panella, J. O. Velez, A. J. Lambert, and G. L. Campbell. 2014. T cell immunity to DENV and ZIKV infections. Human T lymphocyte responses to DENV and ZIKV infections. J. Badolato-Corrêa et al. 205
33. Song, H., J. Qi, J. Haywood, Y. Shi, and G. F. Gao. 2016. Zika virus NS1 structure reveals diversity of electrostatic surfaces among flaviviruses. Nat. Struct. Mol. Biol. 23:456–458.
34. Foo, S.-S., W. Chen, Y. Chan, J. W. Bowman, L.-C. Chang, Y. Choi, J. S. Yoo, J. Ge, G. Cheng, A. Bonnin, et al. 2017. Asian Zika virus strains target CD14+ blood monocytes and induce M2-skewed immunosuppression during pregnancy. Nat. Microbiol. 1.
35. Sallusto, F., and A. Lanzavecchia. 2009. Heterogeneity of CD4+ memory T cells: functional modules for tailored immunity. Eur. J. Immunol. 39:2076–2082.
36. Loetscher, M., B. Gerber, P. Loetscher, S. A. Jones, L. Piali, I. Clark-Lewis, M. Baggiolini, and B. Moser. 1996. Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J. Exp. Med. 184:963–969.
37. Farber, J. M. 1997. Mig and IP-10: CXC chemokines that target lymphocytes. J. Leukoc. Biol. 61:246–257.
38. Gao, P., X.-Y. Zhou, Y. Yashiro-Ohtani, Y.-F. Yang, N. Sugimoto, S. Ono, T. Nakanishi, S. Obika, T. Imanishi, T. Egawa, et al. 2003. The unique target specificity of a nonpeptide chemokine receptor antagonist: selective blockade of two Th1 chemokine receptors CCR5 and CXCR3. J. Leukoc. Biol. 73:273–280.
39. Sierra, B., A. B. Perez, G. Garcia, E. Aguirre, M. Alvarez, D. Gonzalez, and M. G. Guzman. 2014. Role of CC chemokine receptor 1 and two of its ligands in human dengue infection. Three approaches under the Cuban situation. Microbes Infect. 16:40–50.
40. de-Oliveira-Pinto, L. M., C. F. Marinho, T. F. Povoa, E. L. de Azeredo, L. A. de Souza, L. D. R. Barbosa, A. R. C. Motta-Castro, A. M. B. Alves, C. A. L. Ávila, L. J. de Souza, et al. 2012. Regulation of inflammatory chemokine receptors on blood T cells associated to the circulating versus liver chemokines in dengue fever. PLoS ONE. 7:e38527.
41. Böttcher, J. P., M. Beyer, F. Meissner, Z. Abdullah, J. Sander, B. Höchst, S. Eickhoff, J. C. Rieckmann, C. Russo, T. Bauer, et al. 2015. Functional classification of memory CD8(+) T cells by CX3CR1 expression. Nat. Commun. 6:8306.
42. Weiskopf, D., D. J. Bangs, J. Sidney, R. V. Kolla, A. D. De Silva, A. M. de Silva, S. Crotty, B. Peters, and A. Sette. 2015. Dengue virus infection elicits highly polarized CX3CR1+ cytotoxic CD4+ T cells associated with protective immunity. Proc. Natl. Acad. Sci. U. S. A. 112:E4256–E4263.
43. Hsieh, M.-F., S.-L. Lai, J.-P. Chen, J.-M. Sung, Y.-L. Lin, B. A. Wu-Hsieh, C. Gerard, A. Luster, and F. Liao. 2006. Both CXCR3 and CXCL10/IFN-inducible protein 10 are required for resistance to primary infection by dengue virus. J. Immunol. Baltim. Md. 190:1785–1863.
44. Sandberg, J. K., N. M. Fast, and D. F. Nixon. 2001. Functional heterogeneity of cytokines and cytolytic effector molecules in human CD8+ T lymphocytes. J. Immunol. Baltim. Md. 190:167:181–187.
45. Lichterfeld, M., X. G. Yu, M. T. Waring, S. K. Mui, M. N. Johnston, D. Cohen, M. M. Addo, J. Zaunders, G. Alter, E. Pae, et al. 2004. HIV-1-specific cytotoxicity is preferentially mediated by a subset of CD8(+) T cells producing both interferon-gamma and tumor necrosis factor-alpha. Blood 104:487–494.
46. Lindow, J. C., N. Borochoff-Porte, A. P. Durbin, S. S. Whitehead, K. A. Fimlaid, J. Y. Bunn, and B. D. Kirkpatrick. 2012. Primary vaccination with low dose live dengue 1 virus generates a proinflammatory, multifunctional T cell response in humans. PLoS Negl. Trop. Dis. 6:e1742.
47. Gideon, H. P., M. S. Hamilton, K. Wood, D. Pepper, T. Oni, R. Seldon, C. Barwell, P. R. Langford, R. J. Wilkinson, and K. A. Wilkinson. 2013. Impairment of IFN-gamma response to synthetic peptides of Mycobacterium tuberculosis in a 7-day whole blood assay. PLoS One. 8:e71351.
48. Azeredo, E. L., S. M. Zagne, M. A. Santiago, A. S. Gouvea, A. A. Santana, P. C. Neves-Souza, R. M. Nogueira, M. P. Miagostovich, and C. F. Kubelka. 2001. Characterisation of lymphocyte response and cytokine patterns in patients with dengue fever. Immunobiology 204:494–507.
49. Fuentes-Miranda, C. J., F. J. Sánchez-Garcia, A. R. Coker, O. Rojas-Espinosa, R. Salinas-Tobón, and M. M. B. Moreno-Altimirano. 2014. Dengue virus serotype-2 impairs proliferation of healthy donors’ T lymphocytes. Intervirology 57:83–92.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of this article at the publisher’s web-site.

Table S1. Monoclonal antibodies used in this study.